tirzepatide drinking alcohol and Tirzepatide: Safety Tips for Weight Loss Could a medication used for

The results of the trial showed that semaglutide was associated with less hunger and food cravings, better control of eating, and a lower preference for high-fat foods

Contact your healthcare provider if you experience persistent fatigue, shortness of breath with minimal exertion, dizziness, pale skin, rapid heartbeat, severe gastrointestinal symptoms lasting more than 48-72 hours, or inability to maintain adequate food or fluid intake

Typical Early Side Effects Nausea (most common) - Usually peaks in the first few days after injection, tends to improve significantly over 2-3 weeks, and often decreases with each subsequent dose increase Digestive Changes - Mild constipation or diarrhea, changes in bowel habits, and reduced appetite Other Common Experiences - Mild headaches, temporary fatigue, slight dizziness, and minor injection site reactions Strategies for Minimizing Discomfort Your Freya Meds physician will provide personalized guidance, but many patients find these strategies helpful: For Nausea: Eat smaller, more frequent meals rather than large portions, avoid lying down immediately after eating, choose bland, easy-to-digest foods during adjustment periods, stay well-hydrated throughout the day, and time your injection for when you can rest if needed

All descriptions are based on publicly available information from the company's website

in all patients we followed Hct for 1 year to identify those who developed new ERY defined as Hct50%

Semaglutide (Ozempic, Wegovy) is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist, while tirzepatide (Mounjaro, Zepbound) is a dual-acting glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist